Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent main...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., Usmani, Saad Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275699/
https://www.ncbi.nlm.nih.gov/pubmed/36827681
http://dx.doi.org/10.1182/bloodadvances.2022009138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275699/
https://www.ncbi.nlm.nih.gov/pubmed/36827681
http://dx.doi.org/10.1182/bloodadvances.2022009138

Ejemplares similares